HBOT Conversations:
Dr. Paul Harch & Inflammation
Dr. Paul G. Harch, M.D. has used hyperbaric oxygen therapy to treat more than 100 different conditions, including stroke, dementia, autism, and traumatic brain injury. His goal is to help his patients get their lives back using hyperbaric oxygen therapy.
He is the author of The Oxygen Revolution and is considered an International expert and pioneer in the field of Hyperbaric Oxygen Therapy (HBOT). His informative, and comprehensive guide on HBOT has helped countless souls better understand what HBOT is and how it directly affects the body at the genetic level.
This episode on Inflammation is the first in a 9 episode series that will be released weekly with Dr. Harch.
Watch the Podcast
HBOT News podcast host, Edward di Girolamo, talks with special guest and HBOT expert, Dr. Paul G. Harch, MD. This is the first of nine episodes with Dr. Harch examining the God-given miracle of Hyperbaric Oxygen Therapy.
In this episode, we dive into how HBOT is a game-changer for inflammation. Harch explains that inflammation is the driving factor for countless chronic illnesses, but thankfully Hyperbaric Oxygen Therapy is a natural proven way to suppress inflammation.
Harch summarizes a fascinating study done in 2008, by Dr. Cassandra Godman. Her team took skin biopsies and extracted the normal tissue, then they examined the cells that lined the tiniest blood vessels in the tissue. Next, they put these cells in a petri dish and put them in a hyperbaric chamber and gave him a single hyperbaric treatment. Afterwards, they did a mass gene array analysis for 48 hours. What happened next was ground-breaking in better understanding the role that HBOT has on inflammation.
At the end of 24 hours 8,101 of our 19,000 protein coding genes in our 23 chromosomes were either significantly turned on or turned off & suppressed. That single HBOT treatment turned on the anti-inflammatory genes and the growth and repair hormone genes, and the largest cluster suppressed were the pro-inflammatory genes.
Our inflammatory reaction is inescapable when an injury occurs. But, when the patient receives hyperbaric oxygen therapy treatment after an injury (the sooner the better), it can have an overwhelming positive influence on the inflammatory reaction at any place along the spectrum. Harch continues to explain that the anti-inflammatory effects of hyperbaric oxygen are wide-ranging.
Harch spoke of the Navy’s experience with Hyperbaric Oxygen Therapy, as the Navy really kind of dominated this field for many years. The Navy reported that if you can get someone in a chamber within one hour of coming out of the water – when they’re symptomatic for decompression sickness – then the first hyperbaric treatment is curative in 90% of cases. Everyone thought that HBOT was treating bubbles in the brain at that point, but the reality is they were treating inflammation. We now know that it’s the inflammatory reaction in the brain after the bubbles passed that Hyperbaric Oxygen Therapy is treating; not the bubbles.
HBOT isn’t new, it dates back well over a hundred years. It’s still misunderstood, because many believe that HBOT therapy is a treatment for diseases. But, the reality is that HBOT is a treatment for disease processes, and it’s these processes that cause the diseases. We treat the inflammation that causes the disease processes, and in turn we treat the disease. That’s the power of Hyperbaric Oxygen Therapy.
Stay tuned for all nine episodes that will be release each Friday for the next eight weeks.
Guest
Dr. Paul G. Harch, MD
Dr. Paul G. Harch, M.D. is a clinician in emergency medicine and hyperbaric medicine who is the former director of the University Medical Center Hyperbaric Medicine Department and LSU Hyperbaric Medicine Fellowship. Currently, he is a Clinical Professor of Medicine in the Section of Emergency Medicine at LSU School of Medicine in New Orleans. He graduated from the Johns Hopkins University School of Medicine after graduating from the University of California at Irvine with magna cum laude/Phi Beta Kappa honors.
Dr. Harch initiated and continues to be a private practice that has resulted in the largest case experience in neurological hyperbaric medicine in the world. In this practice, he adapted the concepts of conventional hyperbaric oxygen therapy to wounds in the central nervous system, which spawned the subsequent academic and research practice. Harch HBOT is the best place to receive oxygen therapy treatments, and patients have traveled from more than 50 countries to be treated by Dr. Harch himself.
Harch HBOT – Hyperbaric Oxygen Therapy Clinic
5216 Lapalco Blvd.
Marrero, LA
504-309-4948
hbot@hbot.com
https://hbot.com/
Subscribe Now, It’s Free !
Recent HBOT News
Clinical Trial – Quality of Recovery After General or Spinal Anesthesia for Inguinal Hernia Repair
Different anesthetic techniques have been proposed for carrying out Inguinal hernia repair,
including local anesthesia, regional and general. There are no recent data on the application
of a validated questionnaire to assess which anesthetic technique, local infiltration under
general anesthesia or spinal anesthesia, would provide better quality of recovery in the
opinion of the patients undergoing inguinal hernia repair. The aim of the study is to perform
a randomized clinical trial comparing the quality of recovery (QoR-40) after local
infiltration under general anesthesia via laryngeal mask (LMA) or spinal anesthesia for
unilateral inguinal hernia repair. METHODS – Seventy patients aged 18 to 65 years old, who
were scheduled to undergo unilateral inguinal hernia repair at Santa Lucinda Hospital will be
enrolled in the study. The anesthesia will be performed according to the following sequence:
L Group – intravenous (I.V.) propofol and alfentanyl, followed by LMA positioning. The
anesthesia will be maintained by propofol. For local anesthesia, approximately 50 ml of 0.5%
ropivacaine will be infiltrated along the line of incision in the subcutaneous plane,
followed by peripheral nerve block technique (e.g., ilioinguinal-hypogastric nerve block) and
local wound infiltration at the fascial level. S Group – spinal puncture followed by
intrathecal 15 mg of 0.5% hyperbaric bupivacaine injection and sedation with propofol by
continuous infusion. Pain will be assessed every 15 minutes at Post-anesthesia Care Unit
(PACU) using a 0-10 numeric pain rating scale and I.V. morphine will be administered to
maintain the pain score below 4. The QoR-40 will be administered by a blind investigator 24
hours after surgery.
Clinical Trial – Fascia Iliaca Compartment Block for Proximal-end Femur Fractures
Fracture femur is a common injury which is associated with excruciating pain. Positioning for
neuraxial blocks is always challenging because even slight overriding of the fracture ends is
intensely painful .It can causing major patient distress which accompanied by well-known
physiological sequelae such as sympathetic activation causing tachycardia, hypotension, and
increased cardiac work that may compromise high-risk cardiac patients.
Fascia iliaca compartment block is highly effective in blocking lateral cutaneous nerve of
the thigh and femoral nerve. Fascia iliaca compartment block is not only easy to perform but
it is also associated with minimal risk as the local anesthetic is injected at a safe
distance from the femoral artery and femoral nerve. It is always safe to perform the fascia
iliaca compartment block prior to spinal anesthesia as the patient can respond during
administration of the local anesthetic and can prevent intra-neuronal injections
MicroRNA-148b is a potential prognostic biomarker and predictor of response to radiotherapy in non-small-cell lung cancer.
Abstract: miR-148b has been found to be aberrantly expressed in various tumor types. It has recently been reported to be involved in regulating radioresistance in non-small cell lung cancer (NSCLC) cells. However, its expression level and association with...